Co-Diagnostics Shares Rise 21% After Submitting FDA Application For Covid-19 Test Platform
By Ben Glickman
Shares of Co-Diagnostics rose on Wednesday after the company submitted an application to the Food and Drug Administration for its Covid-19 test platform.
The stock was up 21% to $1.39 in midday trading. Shares are down 46% this year.
The Salt Lake City-based company said it had submitted its Co-Dx PCR Covid-19 test to the FDA for Emergency Use Authorization. The company's submission includes its PCR Pro instrument, the Covid-19 detection test and an associated mobile app.
Co-Diagnostics said its polymerase chain reaction technology has been shown in evaluations to detect Covid-19 in nasal swabs with results shown on the app within 30 minutes.
The company is also developing its Co-Dx platform to test for tuberculosis, HPV and certain other respiratory viruses.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 27, 2023 12:52 ET (17:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth